Breast cancer, which is the most common cancer in women, 1 has illustrated most of the recent progresses in personalized medicine in the past years. The latest St Gallen recommendations 2 for early breast cancer (EBC) advocated to assess intrinsic subtypes of breast tumors based on immunohistochemistry (IHC) analysis for the hormonal receptors (HRs), human epidermal growth factor receptor 2 (HER2) and Ki-67, to select the best candidates for adjuvant or preoperative systemic therapies. Indeed, pre-and analytic stages supporting such determinations are critical, and among them is the quality of sampling. In neoadjuvant settings, needle core biopsy (NCB) specimens are, until the final surgery, the only available material for invasive carcinoma diagnosis and determination of prognosis and predictive factors. In cases of pathologic complete response, which have become less rare since the implementation of biotherapies, 3 or selection of a tumor subclone under therapeutic pressure, 4 NCB specimens may constitute the only histologic material. Thus, reliability of this material compared with whole Upon completion of this activity you will be able to:
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Materials and Methods

Patients
All patients 18 years or older who had been treated for newly diagnosed EBC in Henri Becquerel Center, Rouen, France, between January 2008 and December 2011 were retrospectively screened. Invasive breast carcinomas 2 cm or larger (pT2-pT4c) with available pretherapeutic NCB specimens and WSS and that were treated first by surgery (mastectomy or lumpectomy) without neoadjuvant treatments were eligible. Inflammatory, multifocal, metastatic, and in situ or microinvasive breast cancers were excluded. For each patient, informed consent for biomedical studies on histologic samples was collected at the time of surgery.
Methods
Sampling
NCBs were performed by a surgeon or a radiologist at the time of initial diagnosis under local anesthesia mostly with a 14-gauge needle. All samples were immediately fixed (for 24 hours) and shipped with minimal delay to the Department of Pathology. WSS (lumpectomy or mastectomy) were incised fresh and formalin fixed after gross examination within a maximum of 30 minutes, for at least 48 hours, depending on the size. The tumor size was assessed on the fresh surgical specimens.
Tissue Processing
Formalin-fixed, paraffin-embedded (FFPE) samples relative to the NCB specimens and WSS were collected, and data regarding preanalytic procedures (surgeon or radiologist, delay of shipment to the laboratory, fixation time) were registered. H&E staining and IHC for the ER, PR, and HER2 were performed using FFPE slides for NCB specimens and WSS, in contrast to analysis of Ki-67, cyclin A, cytokeratin 5 (CK5), and epidermal growth factor receptor (EGFR), which were performed using slides for NCB specimens and a tissue microarray (TMA) for the WSS. All antibody references are detailed in Supplemental Table 1 (supplemental material can be found at http://bit.ly/PetrauOct15). The TMA was constructed with six spots (0.6-mm-thick sections) focusing on the invasive component for each tumor, plus two normal breast spots for external controls. If fewer than two spots per tumor were interpretable (with at least 200 tumor cells/spot), or in cases of discrepancies with the NCB specimens, additional IHC analysis was performed on individual WSS sections.
Histologic Analysis and Definition of Intratumor Heterogeneity
All samples were independently analyzed twice by two well-trained pathologists (A.B. and J.-M.P.), and if discordant, they were submitted to a third pathologist (L.V.).
Data (number and length of biopsy specimens, corresponding length of tumor tissue), the presence of biopsy artifacts (crushing or fixation, defined by cramping interpretation), histologic type, and SBR grade (including MAI, as defined by the Nottingham Grading System 12 ) were assessed on H&E-stained sections for NCB specimens and WSS. Intratumor heterogeneity was assessed only for WSS and was defined as the presence of mixed histologic types or tumor grade within the same sample.
IHC Interpretation
IHC evaluation was restricted to nuclear staining for ER, PR, and Ki-67; cytoplasmic staining for CK5; and membranous staining for EGFR and HER2. HER2 assessment was performed according to the 2007 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) recommendations. 13 All HER2 2+ samples by IHC were tested for amplification by chromogenic in situ hybridization (CISH) (DuoCish SK108 kit; DAKO, Glostrup, Denmark). The positivity cutoffs for each factor are detailed in ❚Table 1❚. Intrinsic subtypes were defined according to the 2011 St Gallen guidelines 14 ❚Table 2❚. The EGFR and CK5 assessments were used to define the basal-like phenotypes among the triple-negative tumors. 15 
Definitions of Concordance Between NCB Specimens and WSS
Histologic type was considered concordant if the same type 16 was determined by NCB specimens and the corresponding WSS. SBR grade was concordant if the same grade (I, II, or III) was defined by NCB specimens and WSS. ER, PR, HER2, Ki-67, cyclin A, EGFR, and CK5 were concordant if NCB specimens and WSS resulted in the same status (positive/negative).
Definition of Major Discordances Between NCB Specimens and WSS
In cases of discrepancies between the NCB specimens and WSS, a major discordance was retained when it potentially affected the treatment according to French recommendations 17 (indication of adjuvant/neoadjuvant chemotherapy, hormonotherapy, or trastuzumab). Consequently, major discordances could be retained in cases of up-or downgrading from SBR I to III or conversion of the HR or HER2 status between the NCB specimens and WSS.
Putative Factors for Discordance
We hypothesized that the tumor size (20-29 mm vs 30-39 mm vs ≥40 mm), number of biopsies (1 or 2 vs 3 or 4 vs 5 or more), ratio number of biopsies/tumor size, presence of intratumor heterogeneity by WSS, or presence of biopsy artifacts constituted putative factors for discrepancies.
Definition of the Interobserver Concordance
An interobserver concordance was defined as the same determination for each histologic or IHC parameter, by NCB specimens or WSS, by the two readers.
Statistical Analysis
Analysis of concordance was performed using the Cohen's k test with the MedCalc computer software (MedCalc Software, Ostend, Belgium). A concordance was defined as excellent if k > 0.9, strong if 0.8 ≤ k ≤ 0.9, moderate if 0.6 ≤ k < 0.8, weak if 0.4 ≤ k < 0.6, and minimal if less than 0.4. 18
Results
Patients, Biopsy Specimens, and Surgical Specimens
Among the 339 patients treated for EBC pT2 or higher between January 1, 2008, and December 31, 2011, a total of 163 tumors from 161 patients were included (two patients had synchronous bilateral tumors). The mean age at diagnosis was 63 years (range, 30-93 years), and the mean delay between biopsy and surgery was 21 days (range, 6-98 days).
The mean number of biopsies per tumor was three (range, 1-9), with a mean length of 24 mm (range, 4-190 mm) and including 15 mm (range, 2-42 mm) of tumor. Artifact cramping interpretation was observed for 31 biopsy specimens (19%). For the WSS, the mean tumor size was 32 mm (range, 20-90 mm) ❚Table 3❚.
Concordance Between NCB Specimens and WSS
Results concerning the histologic analyses are detailed in ❚Table 4❚. The concordance was excellent for the ER, EGFR, and HER2 (completed by CISH if needed) status (k = 0.94, 0.92, and 0.91, respectively). Concordance was strong for the CK5 (k = 0.82) and moderate for the PR, histologic type, intrinsic subtype, and HER2 (by IHC alone) determinations (k = 0.79, 0.74, 0.73, and 0.71, respectively). In contrast, the correlation was weak for Ki-67 (k = 0.55) and minimal for the cyclin A, SBR grade, and MAI determinations (k = 0.31, 0.29, and 0.24, respectively). In particular, the MAI was roughly undervalued by NCB.
Major Discordance Between NCB Specimens and WSS and Potential Clinical Impact
A total of 11 (7%) major discordances were observed ❚Table 5❚. Concerning HR status, three discrepancies were found that showed a negative NCB specimen for ER and PR in contrast to an ER-positive WSS. Among them, one showed mixed histologic types by WSS analysis (HR-negative ductal carcinoma and HR-positive lobular carcinoma), which may potentially explain this discrepancy because © American Society for Clinical Pathology NCB specimens evaluated only the ductal component. For SBR grade, five major discrepancies were observed, and in all cases, the tumor was upgraded when using WSS. These discordances could be explained by intratumor heterogeneity of the two tumors, reduced sampling of invasive carcinomas by NCB for one tumor, and interobserver discordance for the two remaining tumors. For three patients, the HER2 status was nonoverexpressed/nonamplified by NCB but overexpressed/amplified by WSS analysis. Among these three cases, two were related to intratumoral heterogeneity with two histologic types in the same sample ❚Image 1❚ and one involved in heterogeneity of the amplification that was observed using IHC (2+ or 3+) and CISH (amplified or nonamplified) depending on the territories that were assessed.
For the major discordances involving HR or HER2 status, a histologic analysis restricted to the NCB specimens would have seriously affected the systemic treatment (hormonal therapy, trastuzumab). Concerning the SBR grade, it may have changed the decision of preoperative chemotherapy or hormonotherapy, because a higher grade predicts a better response to chemotherapy. 19 
Putative Factors for Discordance
By dividing the tumors into three categories (20-29 mm, 30-39 mm, and ≥40 mm), we found no significant correlation between discordance and tumor size (Supplemental Table 2 ), with the absolute number of biopsy specimens per tumor and the number of biopsy specimens per centimeter of tumor not correlated with the concordance rate (data not shown). In contrast, the intratumor heterogeneity that was observed in the 40 WSS (25%) was significantly associated with a lower correlation when considering histologic type (k = 0.86 vs k = 0.50, P < .01) and PR (k = 0.87 vs k = 0.54, P < .01). Artifacts were not statistically associated with discordance, although we observed a trend for ER, PR, SBR grade, MAI, and histologic type (Supplemental Table 3 ).
Interobserver Concordance
Overall, interindividual concordance was excellent or strong (k = 1 for ER, 0.92 for PR, 0.85 for HER2 by IHC, and 1 for HER2 using IHC that was completed by CISH if needed), except for SBR grade, the MAI, or Ki-67 (k = 0.53, 0.44, and 0.38, respectively). No differences that were dependent on the specimen type were observed (biopsy or surgical specimen) (Supplemental Table 4 ).
Discussion
This retrospective study that was dedicated to large tumors included 163 pT2 or higher breast tumors, with histologic and IHC specifications by NCB and WSS analysis that were comparable to published neoadjuvant and adjuvant breast cancer cohorts. 20, 21 We found good reliability between biopsy specimens and WSS for ER and PR determination but underestimation of the SBR grade or MAI, which may lead to missed opportunities for preoperative chemotherapy. The HER2 status determined by NCB may seem highly reliable, with only three (1.8%) major discordances among 163 tumors: however, such major discordances represent 14% when considering only HER2-positive cases. Moreover, the moderate rate of HER2 status discrepancies must be balanced by the deep therapeutic and survival impact when considering the benefit of anti-HER2 therapies for EBC, especially when using neoadjuvant approaches.
The literature concerning this topic is rare, is heterogeneous, and does not focus specifically on large tumors, which in our point of view constitute a questioned issue. Recently, Dekker et al 22 published a similar retrospective study that evaluated the accuracy of the ER and HER2 determinations by NCB for 122 patients. Nevertheless, among those patients, only 35 (29%) patients were pT2 or higher. An excellent correlation for the ER status (k = 0.97) was reported, which was comparable to our results (k = 0.94). In a recently published meta-analysis of 2,450 patients, Li et al 23 found only a moderate correlation for ER and PR determination (k = 0.78 and 0.66, respectively), but numerous biases, such as various methods and lack of information concerning tumor size, may explain these conflicting results. In our study, three NCB specimens were negative for HR status but positive by WSS analysis. In their study, Dekker et al 22 reported a comparable rate of such false-negative discordances among their review of 2,622 patients. Dekker et al 22 found a slightly weaker correlation for the HER2 status (IHC completed by CISH if needed) (k = 0.81) compared with ours (k = 0.91). Interestingly, discrepancies in this study concerned negativity by WSS analysis of four initially HER2-positive tumors by NCB (without any preoperative treatment), whereas the major discordances in our series concerned only negative NCB specimens with positive WSS. In their meta-analysis, Dekker et al 22 selected three studies 6, 24, 25 that compared the HER2 status by NCB and WSS that were in accordance with 2007 HER2 testing guidelines. 13 Among the 543 tumors analyzed, 56 were HER2 positive by WSS. Among these cases, six NCB specimens were positive for HER2 but negative by WSS analysis, and four NCB specimens were negative for HER2 but positive by WSS analysis. After pooling their own results with data from the literature, Dekker et al 22 reported a 6% falsenegative rate for NCB specimens in determining the HER2 status among 66 positive WSS, instead of 14%, which was found in our study. This difference may be due to the larger tumor size in our study because, among the three studies retained in the meta-analysis, one did not precisely determine the size of the tumors that were analyzed, 24 while the two others included mostly pT1 tumors (67% 6 and 90% 25 ). Finally, our results reinforce the recommendation made by Dekker et al 22 to retest the HER2 and HR statuses by the WSS analysis in cases of a negative determination by NCB.
Recently, the ASCO/CAP published guidelines for HER2 testing in breast cancer. 26 No HER2 retesting of WSS is warranted if the HER2 status is negative by NCB for a grade I, ER-and PR-positive tumor. On the contrary, these guidelines recommend HER2 retesting in cases of negative results by NCB for grade III tumors or in cases of equivocal results (IHC/in situ hybridization conflicting results or small amounts of invasive carcinoma by NCB, evidence of intratumor heterogeneity by WSS analysis). Following those recommendations, we would not have missed any of the three major discordances for the HER2 status (negative by NCB but positive by WSS) because one concerned a grade III tumor and the two remaining displayed intratumor heterogeneity for the histologic type. Concerning the SBR grade and proliferation markers, we found a weak (Ki-67) or minimal (SBR grade, cyclin A, or MAI) correlation. Comparisons among published series are difficult because of the lack of data (cyclin A) or the lack of methodologic consensus (Ki-67). Nevertheless, the SBR grade concordance has been more extensively studied: the largest published series found a concordance rate between 67% and 81%, with a k varying from 0.48 to 0.64. 8, [27] [28] [29] Those results suggest a better concordance than what was found in our study (k = 0.29), but none of these series mentioned the tumor size. In contrast, Andrade and Gobbi 30 published a study with a comparable recruitment to ours (120 patients, median size of tumor of 35 mm) that showed a more similar concordance rate for SBR grade (59%, k = 0.35), suggesting that a more important heterogeneity in large tumors may alter the reliability of the NCB specimen. Intratumor heterogeneity was observed in 25% of the WSS in our series and was associated with discordances, particularly for histologic type and PR. This finding is in agreement with that of Greer et al, 31 who reported a lower concordance rate in particular for PR, Ki-67, and HER2 in cases of heterogeneous tumors. Beyond intratumoral heterogeneity, technical pitfalls and possible subjectivity of interpretation can explain some of our discordances.
Fixation and crushing artifacts may cause underestimation of the mitotic count, which was observed for 19% of ❚Image 1❚ Example of a patient with a mixed tumor with two patterns of expression in an H&E stain for ductal and lobular invasive carcinoma (A) and in immunohistochemistry for E-cadherin (B), estrogen receptor (C), and human epidermal growth factor receptor 2 (D) (×100). 33 for grade, ER, and HER2. Notably, we did not assess the intraobserver concordance, which may also account for some variations of interpretation but is poorly evaluated in the literature. 34, 35 In this study, we did not find a correlation between the reliability of NCB and the number of biopsy specimens, in contrast to the results of Tamaki et al 27 and Greer et al, 31 who reported better reliability in four and five biopsy specimens, respectively, in larger cohorts than ours.
To conclude, this study, which was dedicated to large tumors, confirms that HR assessment using NCB is highly reliable and does not need to be controlled by WSS, whereas HER2 assessment must follow the ASCO/CAP recommendations for HER2 retesting to avoid any false-negative HER2 determinations by NCB (ie, if the result is negative and the sample is limited on the core biopsy specimen) or if the results do not fall in the clearly positive or negative range (IHC or FISH) on the core. On the contrary, determinations of the SBR grade, Ki-67, cyclin A expression, or MAI may be deeply underestimated by NCB because of tumor heterogeneity and the low interobserver concordance regarding those factors. Such markers should be used cautiously when choosing preoperative chemotherapy.
